Fludarabine

製品コードS1491 別名:FaraA, Fludarabinum

Fludarabine化学構造

分子量(MW):285.23

Fludarabineは血管平滑筋細胞の中に一種のSTAT1活性阻害剤で、一種のDNA合成阻害剤です。

サイズ 価格 在庫  
JPY 18156.88 あり
JPY 13966.83 あり
JPY 44636.28 あり
JPY 67674.36 あり
JPY 139668.35 あり

カスタマーフィードバック(4)

  • ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

    Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

  • Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

    Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

製品安全説明書

STAT阻害剤の選択性比較

生物活性

製品説明 Fludarabineは血管平滑筋細胞の中に一種のSTAT1活性阻害剤で、一種のDNA合成阻害剤です。
ターゲット
STAT1 [4]
(Vascular smooth muscle cells)
体外試験

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  NF3jXJpHfW6ldHnvckBCe3OjeR?= MXKyNEDPxE1? NGXXNGMzPCCq NF:xSWpqdmirYnn0d{BmgHC{ZYPzbY9vKG:oIFnEUy=> NUfKWHdQOjV7NEC3NVI>
MV-4-11 MU\BdI9xfG:|aYOgRZN{[Xl? MWiyMlUh|ryP NVK0eFdXPDhiaB?= NV:2XYN3cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MWqyOVEyOTV6Mx?=
THP-1 NHXKfZBCeG:ydH;zbZMhSXO|YYm= M{LhXlIvPSEQvF2= MkHSOFghcA>? NWi0ZoF3cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> NHjlN4MzPTFzMUW4Ny=>
MOLM 13 MkDWRZBweHSxc3nzJGF{e2G7 NYLK[2ZrOi53IN88US=> NGniSXU1QCCq MXTpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NVr1cVZEOjVzMUG1PFM>
KBM3/Bu2506 M3yzSGFxd3C2b4Ppd{BCe3OjeR?= M1r0SVIvPSEQvF2= NXT4R4h1PDhiaB?= NHn6PVhqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> MkWxNlUyOTF3OEO=
Nalm-6 NUGzU5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:0WGlEPTB;MUig{txO MYSyOVA3OTFyMR?=
Reh NXPjdYlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNyIN88US=> M1zqPVI2ODZzMUCx
U2937 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi4UWtFUUN3ME2xOkDPxE1? MYmyOVA3OTFyMR?=
Mec-1 M3jPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL3TWM2OO,:nkWwNEDPxE1? MYqyOVA3OTFyMR?=
RPMI-8226 NIf4S5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfWeG5KSzVyPUWwNEDPxE1? MYSyOVA3OTFyMR?=
Molt-4 M2XEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGwcotKSzVyPUG4NEDPxE1? NGOyOoYzPTB4MUGwNS=>
Nalm-6-FluR NX7WbIRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPaOIdKSzVyPUK1NEDPxE1? NWrUXY9JOjVyNkGxNFE>
Raji  MYLGeY5kfGmxbjDBd5NigQ>? M3;BNlPDqM7:TR?= NYXvNnRsOjRxNEivO|IhcA>? MV7pcoR2[2W|IHHjZ5VufWyjdHnvcpMhd2ZicEWzMEBxPjNiYX7kJJA4O8Li NGrWXG0zPDl2ME[5OS=>
PBMC MWXGeY5kfGmxbjDBd5NigQ>? MUC1NE8yODBizszN M2K4Z|I1KGh? NWHJOGVrTE2VTx?= MYHpcohq[mm2czDTWGFVOSCyaH;zdIhwenmuYYTpc44> M4\wUFI1QTFzOEey
MDA-231 MVzGeY5kfGmxbjDBd5NigQ>? NW\oRVdiOTByIN88US=> MlfNNlQhcA>? M1TubWROW09? MWXk[YNz\WG|ZYOgTWRQKGW6cILld5Nqd25? NYS4cYZIOjR7MUG4O|I>
624.38mel  NEfZOZlHfW6ldHnvckBCe3OjeR?= NYr5fVBxPTBizszN MY[yOEBp MonuSG1UVw>? MlTI[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w MnzaNlQ6OTF6N{K=
MDA-231 NV61XpBCTnWwY4Tpc44hSXO|YYm= NEfCUXk2OC1{MECg{txO NEO3ToozPCCq MXHEUXNQ MkDibY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN? MWiyOFkyOTh5Mh?=
624.38mel  MWDGeY5kfGmxbjDBd5NigQ>? NYHZc|ZbPTBvMkCwJO69VQ>? MnruNlQhcA>? MkDJSG1UVw>? MnXBbY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN? M{\HXFI1QTFzOEey
HMECs MofWSpVv[3Srb36gRZN{[Xl? M3P6cFExOMLizszNxsA> MWOzOuKhcA>? NHrmNGhqdmirYnn0d{BKTk8Qs9MgZY5lKEySUzDpcoR2[2WmIGPURXQyKHCqb4PwbI9zgWyjdHnvckBidmRiSWLGNUBmgHC{ZYPzbY9v MlPiNlQzOTF|Mke=
HMECs  Ml\zSpVv[3Srb36gRZN{[Xl? MUmxNFDDqM7:TdMg M4XyeFM3yqCq MXrpcohq[mm2czDJSm7PucLibXXkbYF1\WRicHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQyKGGwZDDTWGFVOyxiYoX0JI5wfCCxZjDTWGFVOg>? NXPxdldbOjR{MUGzNlc>
BJAB NGrTb29CeG:ydH;zbZMhSXO|YYm= NWnpU2FsPcLizszN NVvRRYEzOjRiaB?= M3rxW4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MUKyOFA2PzF2Nx?=
I-83 MkLXRZBweHSxc3nzJGF{e2G7 NHXOWmE2yqEQvF2= Mn7HNlQhcA>? NULQRXRQcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWLkcGRROjRyNUexOFc>
NALM6 NUDLZllmSXCxcITvd4l{KEG|c3H5 Ml;MOeKh|ryP NV64V4Y3OjRiaB?= M4\DTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NHvyTWUzPDB3N{G0Oy=>
DU-145 M2DlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PEeVAuOTBizsznM41t M{T0TlQ5KGkEoB?= NInkS4VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVH4eVkyOjN5M{S4NVU>
Nalm-6 NFLGU3VHfW6ldHnvckBCe3OjeR?= NFyyeIEyOMLizszN MVuxM|IwPCCq NYGyR2pRcW6mdXPld{BifXSxcHjh[5k> MUOyN|Y5OTJ{Mx?=
Reh M4fMcWZ2dmO2aX;uJGF{e2G7 MUSxNOKh|ryP NXjET2Q1OS9{L{SgbC=> MYDpcoR2[2W|IHH1eI9xcGGpeR?= NFXtSFczOzZ6MUKyNy=>
Nalm-6 MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxKOLKvEGw5qCK|ryP MnrRNlM3QDF{MkO=
Reh M2DtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxKOLKvEGw5qCK|ryP MViyN|Y5OTJ{Mx?=
HEC1A MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOxNFAuPTByIN88US=> M2C0W|I1KGh? MlXSbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFS5NGQzOzV7NU[5Oy=>
AN3CA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S3e|ExOC13MECg{txO M{P5elI1KGh? NHnF[GxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NH3NW48zOzV7NU[5Oy=>
HEC50B NU\1RXRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPuNVAxNTVyMDFOwG0> MorNNlQhcA>? MXnpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> M4LnRlI{PTl3Nkm3
HEC1A NYj4S4J7SXCxcITvd4l{KEG|c3H5 MmPkNlAwOTByIN88US=> M3HHWFI1KGh? MX;pcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1W3eFI{PTl3Nkm3
AN3CA NXq4fphISXCxcITvd4l{KEG|c3H5 M4HOc|IxNzFyMDFOwG0> MmX4NlQhcA>? NWDSTodjcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4PlXlI{PTl3Nkm3
HEC50B M1vncGFxd3C2b4Ppd{BCe3OjeR?= NF7XPHEzOC9zMECg{txO NEHm[ZgzPCCq MULpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NGW5NYwzOzV7NU[5Oy=>
EHEB M{jmdmFxd3C2b4Ppd{BCe3OjeR?= NGjrXXU1OCEQvF2= MkPiNlQhcA>? NXvlb4NCcW6mdXPld{BieG:ydH;zbZM> NYLqUVg5OjN2OUewO|U>
A549 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPZTWM2OD1zNT63xtEzNjhiwsXN NIX0e2wzOzN5N{G5Ni=>
A549 GAPDH-deficient NHX6UnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfFVnVKSzVyPUG4MlXDuTJwMzFCuW0> NEHVcHczOzN5N{G5Ni=>
CLL  MV\BdI9xfG:|aYOgRZN{[Xl? NGr2bncyOCEQvF5CpC=> NIXkWXEzPC17NjDo NVi3fGtIcW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? Ml[xNlIzODd4OE[=
MEC1 MoruRZBweHSxc3nzJGF{e2G7 NGrxNmYyODEEoN88US=> M17RSFczKGh? MWHpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 M3PFTVIzOTN{OUez
U937  M{\IUGFxd3C2b4Ppd{BCe3OjeR?= M2LobVAvQCEQvF2= MojiOE01QCCq M3;6bIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MVmyNlA4PDdyMB?=
U937  MkXWRZBweHSxc3nzJGF{e2G7 MVWxJO69VQ>? Moe1PVYhcA>? MWXpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NEjvUFczOjB{M{WyNy=>
Daudi MXfBdI9xfG:|aYOgRZN{[Xl? NXzR[mtYOjBizszN Mo\mPVYhcA>? NEjuTWFqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> MUeyNlAzOzV{Mx?=
J45.01 Mn\aRZBweHSxc3nzJGF{e2G7 MXuxJO69VQ>? MUK5OkBp M{\ydIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MorXNlIxOjN3MkO=
RPMI 8226 NV3XPWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTXeZlKSzVyPUK1MlnDqMLzwrCzMlch|ryP NUjYTllwOjF7NEiyOlQ>
CEM M1jLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nXXGlEPTB;Mj60xsDDucLiMD60JO69VQ>? MVmyNVk1QDJ4NB?=
Raji MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwNEhCpOKyyqByLkC0JO69VQ>? MoHWNlE6PDh{NkS=
U937 M3T2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjpT3hKSzVyPUCuNlTDqMLzwrCwMlA1KM7:TR?= MofKNlE6PDh{NkS=
K562 NX3HXHRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fDSGlEPTB;MD60OOKhyrIEoECuNFUh|ryP NUP4dFZ2OjF7NEiyOlQ>
NALM-6 MmrJRZBweHSxc3nzJGF{e2G7 MmTGNVAh|ryPwrC= NV[yUWJ4OjRiaB?= NWDURnVRcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?= M{[wSVIyPjl7M{iz
JMV-3 MmfrRZBweHSxc3nzJGF{e2G7 M2\jUFExKM7:TdMg MU[yOEBp MXnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOuaXfoeIx6 NFTCbnEzOTZ7OUO4Ny=>
EHEB NV\5UmYxTnWwY4Tpc44hSXO|YYm= M1;BblUuPTBizszN Ml3ZNlQhcA>? Ml7o[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> NYG3TFhMOjFzNkizPVE>
JVM-2  NVO0UVh5TnWwY4Tpc44hSXO|YYm= M4CxO|MxKM7:TR?= NXn3bWN[OjRiaB?= MY\k[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25? MofpNlEyPjh|OUG=
KBM3/Bu2506 NHvw[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjFdZlSUUN{ME2wMlY4KML3TR?= NFPKOpozODl|M{WwPS=>
KBM3/Bu2506 M3LYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTRclNYOC54IN88US=> M1XWNlI1KGh? NYPyNYh4cW6lcnXhd4V{KHSqZTDj[YxtKG[{YXP0bY9vKGmwIGOtdIhie2V? MljBNlA6OzN3MEm=
MDA-MB-231 M2fQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn4b2xpUUN3ME20MlAh|ryP NUTjOppLOjB2NEezPVA>
MCF-7 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO3doZKSzVyPUG1MlAh|ryP NHrs[WIzODR2N{O5NC=>
HLE-B3  MUjGeY5kfGmxbjDBd5NigQ>? NXK3[HRvOjVizszN NFyzWZI1QCCq NILwb5FjdG:la4OgTWZPNc7|4pETbY5lfWOnZDDTWGFVOSCyaH;zdIhwenmuYYTpc44h[W6mIFnEU{BmgHC{ZYPzbY9v M2fWSFIxPDN3MUW4
K562 NEnFfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG3NkBp NILtUIpKSzVyPUOuN{BvVQ>? NYLBU3RQOjB|MEexPVg>
BW-225 NHTaTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXqc2M2UUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=> MUSxPFY3OTN6MB?=
OH-65 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|IxRTFwM{egx7cyOOLKkklCpO69VcLi MUexPFY3OTN6MB?=
GR-145 NVnsdVVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|IxRTJwN{Sgx7chOTEkiKK4JEDPxE4EoB?= NH\TbpAyQDZ4MUO4NC=>
A549 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV36cXY3UUN{ME21MlQ5KMPZIEGw5qiTQCEQvF5CpC=> M4PoU|E5PjZzM{iw
CaSki  MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXBTWMzOD1zLkO3JOOYKDFy4pkSO{DPxE4EoB?= MlXWNVg3PjF|OEC=
ZMK-1 NH;Gb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\KTWMzOD1zLkO3JOOYKDFy4pkSOkDPxE4EoB?= M2\EZVE5PjZzM{iw
SKW6.4 NUGyWnViSXCxcITvd4l{KEG|c3H5 NHTZbnoxNjBzLUGwJO69VQ>? NGrOb44zPC92ODDo NGL3[INqdmS3Y3XzJINmdGxiZHXheIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= NGjqfHkyQDB7MkO0NC=>
RPMI 8226 NYHZbotoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\PcG11OjRiaB?= M13sRmlEPTB;MT61OOKh|ryP NYfhbGxnOTd7N{[xPFY>
MM.1S M4jFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zlVlQ5KGh? Mkf3TWM2OD1zMz60POKh|ryP MXuxO|k4PjF6Nh?=
MM.1R NXexclZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\2S3E1QCCq M13YVGlEPTB;M{OuO|kh|ryP M2XjWlE4QTd4MUi2
U937 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HVe2lEPTB;MzyyNFAhyrFiNU[wJI5O NYG0VpJ{OTV7M{CzOlE>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • 濃度: 2 μg/mL
  • 反応時間: 24 hours
  • 実験の流れ:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • 製剤: PBS
  • 投薬量: 40 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 285.23
化学式

C10H12FN5O4

CAS No. 21679-14-1
保管
in solvent
別名 FaraA, Fludarabinum

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01585415 Terminated Metastatic Cancer|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 9, 2012 Phase 1
NCT01503242 Recruiting Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) January 9, 2012 Phase 1
NCT01319565 Active, not recruiting Metastatic Melanoma|Skin Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 9, 2011 Phase 2
NCT01145209 Active, not recruiting Small Lymphocytic Lymphoma|CLL (Chronic Lymphocytic Leukemia) National Heart, Lung, and Blood Institute (NHLBI)|University of Virginia|GlasoSmithKline|National Institutes of Health Clinical Center (CC) June 9, 2010 Phase 2
NCT02500576 Recruiting Melanoma M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.|Prometheus Inc. August 7, 2015 Phase 2
NCT01174121 Recruiting Metastatic Colorectal Cancer|Metastatic Gastric Cancer|Metastatic Pancreatic Cancer|Metastatic Hepatocellular Carcinoma|Metastatic Cholangiocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2010 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • 回答:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT信号経路図

相関STAT製品

Tags: Fludarabineを買う | Fludarabine ic50 | Fludarabine供給者 | Fludarabineを購入する | Fludarabine費用 | Fludarabine生産者 | オーダーFludarabine | Fludarabine化学構造 | Fludarabine分子量 | Fludarabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID